Interestingly, targeting both the PI3K and AR pathways significantly inhibited tumour growth in preclinical models of PTEN resistance and enzalutamide resistance, suggesting potential crosstalk between the pathways and demonstrating the potential for combination therapeutic strategies [2]. The gene discussed is AR; the disease is neoplasm.